UniQure has announced the sale of its commercial manufacturing facility in Lexington, Massachusetts, to Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector production. The deal, valued at $25 million, includes stock and debt. This move comes after UniQure laid off one-fifth of its staff and shuttered another research facility in Lexington in October. As part of the transaction, Genezen will acquire UniQure's commercial gene therapy manufacturing operations, which includes the production of Hemgenix. The sale allows UniQure to outsource the manufacturing of Hemgenix, a gene therapy product. The ticker symbols involved are $QURE and $PFE.
UniQure, with sale of plant, outsources Hemgenix manufacturing https://t.co/Qjx6O0YUD9 $QURE by @NedPagliarulo
Uniqure plans to sell its Lexington, Massachusetts, facility to Genezen, a CDMO that specializes in viral vector production, for $25M in stock & debt. In October, Uniqure laid off "one-fifth of its staff & shuttered a research facility that was also located in Lexington." https://t.co/uYc6Gk5xqG
UniQure, with sale of plant, outsources Hemgenix manufacturing https://t.co/ng4JdrIlyi by @NedPagliarulo $QURE $PFE
$QURE Announces Sale of Commercial Manufacturing Facility to Genezen for $25M https://t.co/cqrlB3YtwJ
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA $QURE https://t.co/XWiDn7skz6
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen $QURE https://t.co/uWXXINjcjy